Related Experiment Video
Updated: Jun 19, 2026
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Medulloblastoma
1Children's Center for Cancer and Blood Diseases, Division of Pediatric Hematology-Oncology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA. gdhall@chla.usc.edu
Insights
Medulloblastoma, a common childhood brain tumor, has survival rates of 85% for standard-risk and 70% for high-risk patients. Further research is needed to improve treatments and reduce side effects, especially in infants.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Molecular Biology
Background:
- Medulloblastoma is the most frequent malignant brain tumor in pediatric patients.
- Patient stratification into standard and high-risk groups is based on age, surgical resection extent, and metastasis.
- Current treatments offer good survival but pose significant risks, particularly for infants.
Purpose of the Study:
- To review the current understanding of medulloblastoma in children.
- To highlight the challenges in treating younger patients due to treatment-related side effects.
- To emphasize the need for advancements in molecular understanding and targeted therapies.
Main Methods:
- Review of existing literature on medulloblastoma diagnosis, risk stratification, and treatment outcomes.
- Analysis of survival data for standard-risk versus high-risk pediatric medulloblastoma patients.
- Discussion of the impact of molecular biology on understanding disease pathogenesis.
Main Results:
- Children over 3 years old have approximately 85% survival for standard-risk and 70% for high-risk medulloblastoma.
- Younger children, especially infants, face a higher risk of adverse treatment effects.
- Molecular biology has advanced understanding but requires further integration into clinical practice.
Conclusions:
- Despite progress, significant challenges remain in medulloblastoma treatment, particularly concerning long-term sequelae in young children.
- Further research into medulloblastoma pathogenesis and molecular pathways is crucial for developing safer and more effective therapies.
- Improved molecular risk stratification is needed to optimize treatment strategies and enhance patient survival while minimizing treatment toxicity.
Abstract:
Medulloblastoma is the most common malignant brain tumor in children. Patients with medulloblastoma are stratified into ''standard'' and ''high'' risk categories based on age at diagnosis, degree of surgical resection, and disease spread. In children older than 3 years of age, the long-term survival can be achieved in approximately 85% of standard risk patients and 70% of high risk patients with a combination of chemotherapy and irradiation. Younger children, particularly infants, are at a significantly higher risk of side-effects of treatment. Despite tremendous progress in the field of molecular biology of medulloblastoma, much remains to be achieved in understanding the pathogenesis, critical pathways responsible for medulloblastoma, and molecular risk stratification, and in devising treatment strategies with even better survival and less long-term sequelae.
